<DOC>
	<DOCNO>NCT01721057</DOCNO>
	<brief_summary>The purpose study determine whether baricitinib 4 milligram ( mg ) daily ( QD ) superior placebo treatment participant moderately severely active Rheumatoid Arthritis ( RA ) inadequate response intolerant least 1 conventional disease-modifying antirheumatic drug ( cDMARD ) ( cDMARD-IR [ inadequate response ] participant ) receive biologic disease-modifying antirheumatic drug ( DMARD ) .</brief_summary>
	<brief_title>A Study Moderate Severe Rheumatoid Arthritis Participants</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Have diagnosis adultonset Rheumatoid Arthritis ( RA ) define American College Rheumatology/ European League Against Rheumatism ( ACR/EULAR ) 2010 Criteria Classification RA Have moderately severely active RA define presence least 6/68 tender joint least 6/66 swollen joint Have Creactive protein ( CRP ) highsensitivity Creactive protein ( hsCRP ) measurement â‰¥ ( great equal ) 1.2 time upper limit normal ( ULN ) Have insufficient response intolerant conventional diseasemodifying antirheumatic drug ( cDMARDs ) either : Have regular use cDMARD least 12 week prior study entry continuous , nonchanging dose least 8 week prior study entry For participant receive cDMARD time entry , investigator document participant 's history participant fail , unable tolerate , contraindication treatment cDMARD Are currently receive corticosteroid dos &gt; ( great ) 10 mg per day prednisone ( equivalent ) receive unstable dose regimen corticosteroid within 2 week study entry within 6 week plan randomization Have start treatment nonsteroidal antiinflammatory drug ( NSAIDs ) receive unstable dose regimen NSAIDs within 2 week study entry within 6 week plan randomization Are currently receive concomitant treatment methotrexate ( MTX ) , hydroxychloroquine , sulfasalazine combination 3 cDMARDs Have ever receive biologic DMARD Have receive interferon therapy within 4 week prior study entry anticipate require interferon therapy study Have receive parenteral corticosteroid administer intramuscular intravenous ( IV ) injection within 2 week prior study entry within 6 week prior plan randomization anticipate require parenteral injection corticosteroid study Have 3 joint injected intraarticular corticosteroid hyaluronic acid within 2 week prior study entry within 6 week prior plan randomization Have active fibromyalgia , investigator 's opinion , would make difficult appropriately assess RA activity purpose study Have diagnosis systemic inflammatory condition RA , , limit juvenile chronic arthritis , spondyloarthropathy , Crohn 's disease , ulcerative colitis , psoriatic arthritis , active vasculitis gout ( participant secondary Sjogren 's syndrome exclude . ) Have diagnosis Felty 's syndrome Have major surgery within 8 week study entry require major surgery study , opinion investigator consultation Lilly designee , would pose unacceptable risk participant Have experience follow within 12 week study entry : myocardial infarction , unstable ischemic heart disease , stroke , New York Heart Association stage IV heart failure Have history presence cardiovascular , respiratory , hepatic , gastrointestinal , endocrine , hematological , neurological , neuropsychiatric disorder serious and/or unstable illness , opinion investigator , could constitute risk take investigational product could interfere interpretation data Are largely wholly incapacitated permit little self care , , bedridden confine wheelchair Have estimate glomerular filtration rate ( eGFR ) base recent available serum creatinine use Modification Diet Renal Disease ( MDRD ) method &lt; ( less ) 40 milliliter per minute per 1.73 m^2 ( mL/min/1.73 m^2 ) Have history chronic liver disease recent available aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 1.5 time ULN recent available total bilirubin &gt; /=1.5 time ULN Have history , lymphoproliferative disease ; sign symptom suggestive possible lymphoproliferative disease , include lymphadenopathy splenomegaly ; active primary recurrent malignant disease ; remission clinically significant malignancy &lt; 5 year Have expose live vaccine within 12 week prior plan randomization expect need/receive live vaccine course study ( exception herpes zoster vaccination ) Have current recent clinically serious viral , bacterial , fungal , parasitic infection Have symptomatic herpes zoster infection within 12 week prior study entry Have history disseminated/complicated herpes zoster ( eg , multidermatomal involvement , ophthalmic zoster , central nervous system involvement , postherpetic neuralgia ) Are immunocompromised , opinion investigator , unacceptable risk participate study Have history active hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Have screen laboratory test value , include thyroidstimulating hormone ( TSH ) , outside reference range population investigative site , opinion investigator , pose unacceptable risk participant 's participation study Have screen electrocardiogram ( ECG ) abnormality , opinion investigator sponsor , clinically significant indicate unacceptable risk participant 's participation study ( eg , Fridericia 's correct QT interval &gt; 500 millisecond [ msec ] men &gt; 520 msec woman ) Have symptomatic herpes simplex time study enrollment Have evidence active latent tuberculosis ( TB )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>